A Non Randomized, Open Label, Single Center Study to Evaluate the Irritation and Sensitization Potential of Baby Products in Healthy Volunteer Children using Primary Irritation Test.

Background and Introduction

The early years are recognized as crucial for children’s healthy development, and proper skincare is considered essential for their long-term well-being. During childhood and adolescence, the skin undergoes several changes, highlighting the need for skincare products to be both safe and effective. Baby products, commonly used to moisturize and protect the skin are to be carefully evaluated to ensure they do not cause irritation or sensitization, particularly since children’s skin is more delicate than that of adults.

Participants with varied skin types were included to determine whether the product is safe for use in children and adolescents. The aim of the study was to provide essential data to confirm the product’s safety, enabling its confident recommendation by parents, caregivers, and healthcare professionals.

Purpose of the Study

The purpose of the study was to evaluate the irritation and sensitization potential of baby products when applied to the skin of healthy children and adolescents aged 5 to 18 years. A primary irritation test was conducted under controlled occlusive conditions to assess the dermatological safety of the products and confirm their suitability for use on sensitive skin. The findings contributed to confirming that the products met safety standards and could be confidently recommended for pediatric use.

Results

The study was conducted over a 7**- day period** for each participant.A total of 24 healthy children (12 males and 12 females) aged 5 to 18 years were enrolled who successfully completed the study. The average age of participants was 12.9 years. The study assessed four baby care products: Bumsuit Baby Cream, Lotion, Massage Oil, and Shampoo.

Primary Endpoint: No signs of erythema (redness), edema (swelling), dryness, or peeling were observed in any subject during the study. All participants consistently recorded a score of zero on the Draize scale, confirming that the products were non-irritating and well-tolerated.

Secondary Endpoint: None of the participants reported sensations of burning, itching, tingling, or other signs of allergic skin reactions. There were no instances of acute or delayed sensitization observed throughout the study period.

Safety Outcomes: No adverse events (AEs) or serious adverse events (SAEs) were reported. Compliance was 100%, and no protocol deviations or subject withdrawals occurred.